Most #vaccines need to be kept at 4-8°C, hard to do in many parts of the world. #EUfunded #MACIVIVA project has developed innovative needle-free formulations & managed to keep an HIV vaccine candidate stable at temps of up to 40°C #H2020 #IndTech2018 … https://t.co/aw6uBdoIEg

Most #vaccines need to be kept at 4-8°C, hard to do in many parts of the world. #EUfunded #MACIVIVA project has developed innovative needle-free formulations & managed to keep an HIV vaccine candidate stable at temps of up to 40°C #H2020 #IndTech2018
… https://t.co/aw6uBdoIEg

— PRAATNEDERLANDS Ⓥ (@praatnederlands) October 30, 2018

from Twitter https://twitter.com/praatnederlands #euiapress #euinternationalacademy more #EUIAOJ at https://ift.tt/2GeCjyM